Hybrid imaging with [ <sup>68</sup>Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Aim

To compare [ ⁶⁸Ga]PSMA-11 PET-CT, [ ⁶⁸Ga]PSMA-11 PET-MRI and MRI in a cohort of prostate cancer (PCa) patients in biochemical recurrence after initial curative therapy.

Materials and methods

Fifty-three patients with biochemically recurrent PCa underwent whole-body [ ⁶⁸Ga]PSMA-11 PET-CT 1 hour post-injection (p.i.) followed by [ ⁶⁸Ga]PSMA-11 PET-MRI 2.5 hours p.i., including a multiparametric MRI pelvic protocol examination. Imaging data analysis consisted of visual (qualitative) evaluation of the PET-CT, PET-MRI and MRI scans, as well as semi-quantitative and quantitative analyses of the PET and MRI data, including calculation of the parameters standardized uptake value (SUV) and apparent diffusion coefficient (ADC) derived from the PCa lesions. Association analysis was performed between imaging and clinical data, including PSA level and Gleason score. The results were considered significant for p-values less than 0.05 ( p < 0.05).

Results

The hybrid imaging modalities [ ⁶⁸Ga]PSMA-11 PET-CT and PET-MRI were positive in more patients than MRI alone. In particular, PET-CT detected lesions suggestive of PCa relapse in 34/53 (64.2%), PET-MRI in 36/53 (67.9%) and MRI in 23/53 patients (43.4%). While no significant differences in lesion detection rate were observed between PET-CT and PET-MRI, the latter was particularly efficient in detection of local recurrences in the prostate bed mainly due to the contribution of the MRI part of the modality. Association analysis revealed a statistically significant increase in the probability of a positive scan with increasing PSA levels for all imaging modalities. Accordingly, there was no significant association between scan positivity rate and Gleason score for any imaging modality. No significant correlation was observed between SUV and ADC values in lymph node metastases.

Conclusion

[ ⁶⁸Ga]PSMA-11 PET-CT and PET-MRI provide equally good detection rates for PCa recurrence, both outperforming stand-alone MRI.

Related collections

Most cited references 38

Record: found
Abstract: found
Article: not found

User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability.

Paul A Yushkevich, Joseph Piven, Heather Cody Hazlett … (2006)

Active contour segmentation and its robust implementation using level set methods are well-established theoretical approaches that have been studied thoroughly in the image analysis literature. Despite the existence of these powerful segmentation methods, the needs of clinical research continue to be fulfilled, to a large extent, using slice-by-slice manual tracing. To bridge the gap between methodological advances and clinical routine, we developed an open source application called ITK-SNAP, which is intended to make level set segmentation easily accessible to a wide range of users, including those with little or no mathematical expertise. This paper describes the methods and software engineering philosophy behind this new tool and provides the results of validation experiments performed in the context of an ongoing child autism neuroimaging study. The validation establishes SNAP intrarater and interrater reliability and overlap error statistics for the caudate nucleus and finds that SNAP is a highly reliable and efficient alternative to manual tracing. Analogous results for lateral ventricle segmentation are provided.

0 comments Cited 1948 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

Philip Cornford, Roderick van den Bergh, Erik Briers … (2020)

To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC).

0 comments Cited 387 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Philip Cornford, Joaquim Bellmunt, MICHEL BOLLA … (2017)

To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC).

0 comments Cited 343 times – based on 0 reviews      Review now

All references

Author and article information

Contributors

C. Sachpekidis:

ORCID: http://orcid.org/0000-0001-8739-8741

christos_saxpe@yahoo.gr , c.sachpekidis@dkfz-heidelberg.de

Journal

Journal ID (nlm-ta): Cancer Imaging

Journal ID (iso-abbrev): Cancer Imaging

Title: Cancer Imaging

Publisher: BioMed Central (London )

ISSN (Print): 1740-5025

ISSN (Electronic): 1470-7330

Publication date (Electronic): 22 September 2022

Publication date PMC-release: 22 September 2022

Publication date Collection: 2022

Volume: 22

Electronic Location Identifier: 53

Affiliations

[1 ]GRID grid.7497.d, ISNI 0000 0004 0492 0584, Department of Radiology, , German Cancer Research Center (DKFZ), ; Heidelberg, Germany

[2 ]GRID grid.7700.0, ISNI 0000 0001 2190 4373, Medical Faculty, , Ruprecht-Karls-University Heidelberg, ; 69120 Heidelberg, Germany

[3 ]GRID grid.7497.d, ISNI 0000 0004 0492 0584, Department of Biostatistics, , German Cancer Research Center (DKFZ), ; Heidelberg, Germany

[4 ]GRID grid.7497.d, ISNI 0000 0004 0492 0584, Clinical Cooperation Unit Nuclear Medicine, , German Cancer Research Center (DKFZ), ; Im Neuenheimer Feld 280, 69210 Heidelberg, Germany

Author information

C. Sachpekidis http://orcid.org/0000-0001-8739-8741

Article

Publisher ID: 489

DOI: 10.1186/s40644-022-00489-9

PMC ID: 9502876

PubMed ID: 36138437

SO-VID: 171ded0f-01f4-484e-9651-854713271499

License:

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

History

Date received : 14 June 2022

Date accepted : 6 September 2022

Funding

Funded by: Deutsches Krebsforschungszentrum (DKFZ) (1052)

Open Access :

Open Access funding enabled and organized by Projekt DEAL.

Custom metadata

Keywords: [68ga]psma-11 ligand,pet-ct,pet-mri,prostate cancer recurrence,suv,adc

Data availability:

Keywords: [68ga]psma-11 ligand, pet-ct, pet-mri, prostate cancer recurrence, suv, adc